17/120
0.7 / 5 stars
All 120 Win/Lose results shown below
ATYR Roast Me summary
aTYR PHARMA INC (ATYR). Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth Lose; EPS growth Lose.
Trailing 1 year (4 quarters): 2 wins, 10 lossesLast fetched: 25 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseATYR / S&P -23.46% / 15.20% |
LoseATYR / S&P ATYR unavailable / 15.00% |
LoseATYR / S&P ATYR unavailable / 50.40% |
| 2026-Q11/3 |
WinATYR / S&P -0.38% / -4.33% |
LoseATYR / S&P ATYR unavailable / 11.30% |
LoseATYR / S&P ATYR unavailable / 27.70% |
| 2025-Q41/3 |
WinATYR / S&P 8.60% / 2.65% |
LoseATYR / S&P -19.15% / 9.00% |
LoseATYR / S&P ATYR unavailable / 13.40% |
| 2025-Q30/3 |
LoseATYR / S&P -85.78% / 8.12% |
LoseATYR / S&P -19.15% / 4.61% |
LoseATYR / S&P ATYR unavailable / 13.45% |
| 2025-Q21/3 |
WinATYR / S&P 67.88% / 10.94% |
LoseATYR / S&P -100.00% / 4.83% |
LoseATYR / S&P ATYR unavailable / 10.63% |
| 2025-Q10/3 |
LoseATYR / S&P -16.57% / -4.27% |
LoseATYR / S&P -100.00% / 4.98% |
LoseATYR / S&P ATYR unavailable / 10.57% |
| 2024-Q41/3 |
WinATYR / S&P 105.68% / 2.41% |
LoseATYR / S&P -33.43% / 5.25% |
LoseATYR / S&P ATYR unavailable / 6.15% |
| 2024-Q31/3 |
WinATYR / S&P 12.82% / 5.89% |
LoseATYR / S&P -97.81% / 5.89% |
LoseATYR / S&P ATYR unavailable / 6.11% |
| 2024-Q20/3 |
LoseATYR / S&P -20.00% / 4.28% |
LoseATYR / S&P -94.34% / 5.38% |
LoseATYR / S&P ATYR unavailable / 5.12% |
| 2024-Q11/3 |
WinATYR / S&P 38.30% / 10.56% |
LoseATYR / S&P ATYR unavailable / 5.71% |
LoseATYR / S&P ATYR unavailable / 5.59% |
| 2023-Q40/3 |
LoseATYR / S&P -10.76% / 11.69% |
LoseATYR / S&P -96.60% / 6.81% |
LoseATYR / S&P ATYR unavailable / 7.78% |
| 2023-Q30/3 |
LoseATYR / S&P -26.85% / -3.27% |
LoseATYR / S&P ATYR unavailable / 7.52% |
LoseATYR / S&P ATYR unavailable / -5.03% |
| 2023-Q20/3 |
LoseATYR / S&P 2.86% / 8.74% |
LoseATYR / S&P ATYR unavailable / 9.50% |
LoseATYR / S&P ATYR unavailable / -8.57% |
| 2023-Q10/3 |
LoseATYR / S&P -4.11% / 7.50% |
LoseATYR / S&P ATYR unavailable / 10.77% |
LoseATYR / S&P ATYR unavailable / -15.69% |
| 2022-Q40/3 |
LoseATYR / S&P -27.00% / 7.56% |
LoseATYR / S&P ATYR unavailable / 11.88% |
LoseATYR / S&P ATYR unavailable / -17.99% |
| 2022-Q31/3 |
WinATYR / S&P 6.01% / -4.88% |
LoseATYR / S&P ATYR unavailable / 13.47% |
LoseATYR / S&P ATYR unavailable / -1.41% |
| 2022-Q20/3 |
LoseATYR / S&P -47.10% / -16.10% |
LoseATYR / S&P ATYR unavailable / 13.71% |
LoseATYR / S&P ATYR unavailable / 11.04% |
| 2022-Q10/3 |
LoseATYR / S&P -28.38% / -4.60% |
LoseATYR / S&P ATYR unavailable / 15.97% |
LoseATYR / S&P ATYR unavailable / 42.23% |
| 2021-Q40/3 |
LoseATYR / S&P -17.73% / 11.03% |
LoseATYR / S&P -100.00% / 15.00% |
LoseATYR / S&P ATYR unavailable / 96.40% |
| 2021-Q31/3 |
WinATYR / S&P 86.07% / 0.58% |
LoseATYR / S&P ATYR unavailable / 10.77% |
LoseATYR / S&P ATYR unavailable / 69.42% |
| 2021-Q21/3 |
WinATYR / S&P 9.66% / 8.55% |
LoseATYR / S&P ATYR unavailable / 6.58% |
LoseATYR / S&P ATYR unavailable / 51.81% |
| 2021-Q11/3 |
WinATYR / S&P 14.69% / 6.17% |
LoseATYR / S&P ATYR unavailable / -1.06% |
LoseATYR / S&P ATYR unavailable / 7.39% |
| 2020-Q42/3 |
WinATYR / S&P 20.12% / 12.15% |
WinATYR / S&P 2377.49% / -3.72% |
LoseATYR / S&P ATYR unavailable / -33.42% |
| 2020-Q30/3 |
LoseATYR / S&P -27.25% / 8.93% |
LoseATYR / S&P ATYR unavailable / -2.04% |
LoseATYR / S&P ATYR unavailable / -27.10% |
| 2020-Q21/3 |
WinATYR / S&P 58.57% / 20.54% |
LoseATYR / S&P ATYR unavailable / -0.46% |
LoseATYR / S&P ATYR unavailable / -27.11% |
| 2020-Q10/3 |
LoseATYR / S&P -32.85% / -19.60% |
LoseATYR / S&P ATYR unavailable / 3.47% |
LoseATYR / S&P ATYR unavailable / -14.75% |
| 2019-Q41/3 |
WinATYR / S&P 19.14% / 9.07% |
LoseATYR / S&P ATYR unavailable / 5.36% |
LoseATYR / S&P ATYR unavailable / 2.99% |
| 2019-Q30/3 |
LoseATYR / S&P -31.69% / 1.70% |
LoseATYR / S&P ATYR unavailable / 5.02% |
LoseATYR / S&P ATYR unavailable / 0.21% |
| 2019-Q20/3 |
LoseATYR / S&P -33.45% / 4.30% |
LoseATYR / S&P ATYR unavailable / 6.64% |
LoseATYR / S&P ATYR unavailable / 8.65% |
| 2019-Q10/3 |
LoseATYR / S&P 10.89% / 13.65% |
LoseATYR / S&P ATYR unavailable / 8.12% |
LoseATYR / S&P ATYR unavailable / 14.29% |
| 2018-Q40/3 |
LoseATYR / S&P -38.99% / -13.52% |
LoseATYR / S&P ATYR unavailable / 9.05% |
LoseATYR / S&P ATYR unavailable / 18.23% |
| 2018-Q30/3 |
LoseATYR / S&P -10.66% / 7.71% |
LoseATYR / S&P ATYR unavailable / 10.21% |
LoseATYR / S&P ATYR unavailable / 19.06% |
| 2018-Q20/3 |
LoseATYR / S&P -65.66% / 3.43% |
LoseATYR / S&P ATYR unavailable / 9.03% |
LoseATYR / S&P ATYR unavailable / 14.46% |
| 2018-Q10/3 |
LoseATYR / S&P -24.29% / -0.76% |
LoseATYR / S&P ATYR unavailable / 7.68% |
LoseATYR / S&P ATYR unavailable / 12.46% |
| 2017-Q40/3 |
LoseATYR / S&P -30.69% / 6.64% |
LoseATYR / S&P ATYR unavailable / 7.03% |
LoseATYR / S&P ATYR unavailable / 13.82% |
| 2017-Q31/3 |
WinATYR / S&P 48.53% / 4.48% |
LoseATYR / S&P ATYR unavailable / 5.68% |
LoseATYR / S&P ATYR unavailable / 17.57% |
| 2017-Q20/3 |
LoseATYR / S&P -2.86% / 3.09% |
LoseATYR / S&P ATYR unavailable / 4.83% |
LoseATYR / S&P ATYR unavailable / 17.74% |
| 2017-Q11/3 |
WinATYR / S&P 62.79% / 6.07% |
LoseATYR / S&P ATYR unavailable / 3.67% |
LoseATYR / S&P ATYR unavailable / 13.32% |
| 2016-Q40/3 |
LoseATYR / S&P -32.39% / 3.82% |
LoseATYR / S&P ATYR unavailable / 2.09% |
LoseATYR / S&P ATYR unavailable / 7.05% |
| 2016-Q31/3 |
WinATYR / S&P 14.39% / 3.85% |
LoseATYR / S&P ATYR unavailable / 0.20% |
LoseATYR / S&P ATYR unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-28
| Metric | ATYR total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -90.02% | 20.78% |
| Annualized return | -90.02% | 20.78% |
5Y · 2021-09-01 to 2026-08-28
| Metric | ATYR total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -90.17% | 83.14% |
| Annualized return | -37.12% | 12.86% |
10Y · 2016-09-01 to 2026-08-28
| Metric | ATYR total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -98.70% | 319.30% |
| Annualized return | -35.23% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-25.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B |